Supplement to The Asthma Education Quarterly

Volume 12, Number 2 - Summer 2010

References for articles titled:

What’s up with Long-Acting Beta-Agonists?

1. Ducharme et al. Addition of long-acting ß2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Systematic Review 2010 Apr 14; 4:CD005533

2. D'Urzo AD, Jugovic P, Bouchard J, Jhirad R, Tamari I. Safety of long-acting ß2-agonists in the management of asthma. A Primary Care Respiratory Alliance of Canada perspective. Can Fam Physician 2010;56:119-20

3. Joos S et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63:453-462.

4. Sears et al. Long-acting ß-agonists: a review of formoterol safety data from asthma clinical trials. European Respiratory Journal 2009; 33:21-32.

5. Weatherall M, Wijesinghe M, Perrin K, Harwood M, Beasley R. Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy Thorax 2010;65:39-43

6. Wijesinghe M, et al. The risk of asthma mortality with inhaled long acting ß-agonists. Poat Graduate Medical Journal. 2008; 84:467-472

7. Taylor DR. The ß-agonists saga and Its Clinical Relevance: On and On It Goes. American Journal of Respiratory and Critical care Medicine 2009;179:976-978

Taking AIM at asthma

1. Asthma Insight and Management (AIM): A National Survey of Asthma Patients, Public, and Healthcare Practitioners. www.TakingAIMatAsthma. 2009